nodes	percent_of_prediction	percent_of_DWPC	metapath
Ximelagatran—F2—urine—polycystic ovary syndrome	0.094	0.5	CbGeAlD
Ximelagatran—CYP2C9—urine—polycystic ovary syndrome	0.0374	0.199	CbGeAlD
Ximelagatran—F2—adrenal gland—polycystic ovary syndrome	0.018	0.0956	CbGeAlD
Ximelagatran—F2—female gonad—polycystic ovary syndrome	0.0168	0.0892	CbGeAlD
Ximelagatran—F2—endocrine gland—polycystic ovary syndrome	0.0156	0.0829	CbGeAlD
Ximelagatran—CYP2C9—endocrine gland—polycystic ovary syndrome	0.00621	0.033	CbGeAlD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.00451	0.00555	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1A—polycystic ovary syndrome	0.00449	0.00552	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—CRP—polycystic ovary syndrome	0.00445	0.00549	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.00438	0.0054	CbGpPWpGaD
Ximelagatran—CYP2C9—Xenobiotics—CYP1A1—polycystic ovary syndrome	0.00424	0.00522	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—SERPINE1—polycystic ovary syndrome	0.0042	0.00518	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—polycystic ovary syndrome	0.00417	0.00514	CbGpPWpGaD
Ximelagatran—CYP2C9—Tamoxifen metabolism—CYP1A1—polycystic ovary syndrome	0.00408	0.00502	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—GP1BB—polycystic ovary syndrome	0.00405	0.00499	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—CGB5—polycystic ovary syndrome	0.00398	0.00491	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.00378	0.00465	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00378	0.00465	CbGpPWpGaD
Ximelagatran—F2—Complement and Coagulation Cascades—SERPINE1—polycystic ovary syndrome	0.00374	0.00461	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—INS—polycystic ovary syndrome	0.00372	0.00459	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—MTHFR—polycystic ovary syndrome	0.00372	0.00458	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—MANEA—polycystic ovary syndrome	0.00364	0.00449	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00363	0.00447	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—CRP—polycystic ovary syndrome	0.00354	0.00436	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00353	0.00435	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.00343	0.00423	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—SERPINE1—polycystic ovary syndrome	0.00342	0.00421	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00334	0.00411	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00332	0.00409	CbGpPWpGaD
Ximelagatran—CYP2C9—Arachidonic acid metabolism—AKR1C3—polycystic ovary syndrome	0.00324	0.00399	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.0032	0.00394	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00316	0.00389	CbGpPWpGaD
Ximelagatran—F2—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.00315	0.00388	CbGpPWpGaD
Ximelagatran—F2—Peptide ligand-binding receptors—GHRL—polycystic ovary syndrome	0.00311	0.00383	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00309	0.0038	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—ADAMTS7—polycystic ovary syndrome	0.00302	0.00372	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—CPB2—polycystic ovary syndrome	0.00302	0.00372	CbGpPWpGaD
Ximelagatran—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—polycystic ovary syndrome	0.00297	0.00366	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—INS—polycystic ovary syndrome	0.00296	0.00364	CbGpPWpGaD
Ximelagatran—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—polycystic ovary syndrome	0.00293	0.00361	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00282	0.00348	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.00282	0.00347	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—AKR1C2—polycystic ovary syndrome	0.00278	0.00342	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00277	0.00341	CbGpPWpGaD
Ximelagatran—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP17A1—polycystic ovary syndrome	0.00276	0.0034	CbGpPWpGaD
Ximelagatran—CYP2C9—Oxidation by Cytochrome P450—CYP17A1—polycystic ovary syndrome	0.00272	0.00335	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—SERPINE1—polycystic ovary syndrome	0.00272	0.00335	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—PDE3B—polycystic ovary syndrome	0.00272	0.00334	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00256	0.00315	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00253	0.00311	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00243	0.003	CbGpPWpGaD
Ximelagatran—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—polycystic ovary syndrome	0.00241	0.00296	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00241	0.00296	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00235	0.0029	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—RACGAP1—polycystic ovary syndrome	0.00233	0.00286	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00232	0.00286	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00231	0.00285	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—INHBB—polycystic ovary syndrome	0.00229	0.00282	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00227	0.00279	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00227	0.00279	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00225	0.00278	CbGpPWpGaD
Ximelagatran—CYP2C9—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.00224	0.00276	CbGpPWpGaD
Ximelagatran—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.00218	0.00269	CbGpPWpGaD
Ximelagatran—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.00216	0.00265	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00215	0.00265	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00214	0.00263	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00214	0.00263	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.0021	0.00259	CbGpPWpGaD
Ximelagatran—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	0.0021	0.00258	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00209	0.00257	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—RPL37A—polycystic ovary syndrome	0.00205	0.00253	CbGpPWpGaD
Ximelagatran—CYP2C9—Arachidonic acid metabolism—CYP1A1—polycystic ovary syndrome	0.00204	0.00251	CbGpPWpGaD
Ximelagatran—F2—Vitamin B12 Metabolism—IL6—polycystic ovary syndrome	0.002	0.00246	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.002	0.00246	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00194	0.00239	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00194	0.00239	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00194	0.00239	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00189	0.00232	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00181	0.00223	CbGpPWpGaD
Ximelagatran—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.00177	0.00218	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00176	0.00217	CbGpPWpGaD
Ximelagatran—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.00176	0.00217	CbGpPWpGaD
Ximelagatran—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.00174	0.00214	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00173	0.00213	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00172	0.00211	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00171	0.00211	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—LHB—polycystic ovary syndrome	0.00169	0.00208	CbGpPWpGaD
Ximelagatran—F2—Folate Metabolism—IL6—polycystic ovary syndrome	0.00163	0.002	CbGpPWpGaD
Ximelagatran—F2—Peptide ligand-binding receptors—POMC—polycystic ovary syndrome	0.00161	0.00198	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00159	0.00196	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00157	0.00193	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00156	0.00192	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00156	0.00192	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.00155	0.0019	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—IGFBP1—polycystic ovary syndrome	0.00151	0.00186	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.00144	0.00178	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00143	0.00176	CbGpPWpGaD
Ximelagatran—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.00143	0.00176	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.00142	0.00175	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—PLAT—polycystic ovary syndrome	0.00142	0.00175	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00142	0.00175	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00138	0.00169	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—NPB—polycystic ovary syndrome	0.00137	0.00169	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—IGF1—polycystic ovary syndrome	0.00137	0.00169	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.00137	0.00169	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—AKT2—polycystic ovary syndrome	0.00137	0.00169	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00136	0.00167	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00133	0.00164	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00131	0.00162	CbGpPWpGaD
Ximelagatran—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.00131	0.00162	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—SERPINE1—polycystic ovary syndrome	0.0013	0.0016	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.0013	0.0016	CbGpPWpGaD
Ximelagatran—F2—Selenium Micronutrient Network—IL6—polycystic ovary syndrome	0.00129	0.00159	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.00128	0.00157	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00127	0.00157	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.00126	0.00155	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—LMNA—polycystic ovary syndrome	0.00125	0.00154	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00125	0.00154	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00124	0.00153	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00123	0.00152	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00122	0.0015	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00122	0.0015	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00121	0.00149	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.00119	0.00147	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.00119	0.00146	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.00117	0.00144	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00116	0.00142	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00115	0.00141	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00115	0.00141	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—GHRL—polycystic ovary syndrome	0.00112	0.00138	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.0011	0.00136	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—GNAS—polycystic ovary syndrome	0.00109	0.00134	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	0.00108	0.00133	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	0.00108	0.00133	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—ACE—polycystic ovary syndrome	0.00108	0.00133	CbGpPWpGaD
Ximelagatran—F2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.00108	0.00133	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00107	0.00132	CbGpPWpGaD
Ximelagatran—CYP2C9—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.00106	0.00131	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00104	0.00128	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—TCF7L2—polycystic ovary syndrome	0.00104	0.00128	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00101	0.00125	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000986	0.00121	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000941	0.00116	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.000928	0.00114	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000921	0.00113	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	0.000907	0.00112	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000898	0.00111	CbGpPWpGaD
Ximelagatran—F2—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	0.000895	0.0011	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	0.00086	0.00106	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000838	0.00103	CbGpPWpGaD
Ximelagatran—F2—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000821	0.00101	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	0.00082	0.00101	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000815	0.001	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000788	0.000971	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000767	0.000944	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.000758	0.000934	CbGpPWpGaD
Ximelagatran—CYP2C9—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000748	0.000921	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—FST—polycystic ovary syndrome	0.000747	0.00092	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000743	0.000915	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000738	0.000909	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—LHB—polycystic ovary syndrome	0.000729	0.000898	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000713	0.000878	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—IGF1—polycystic ovary syndrome	0.000706	0.00087	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—AKT2—polycystic ovary syndrome	0.000706	0.000869	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	0.000698	0.000859	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.00069	0.00085	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000689	0.000848	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—SCT—polycystic ovary syndrome	0.000683	0.000842	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000675	0.000831	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—LEP—polycystic ovary syndrome	0.000672	0.000828	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—SERPINE1—polycystic ovary syndrome	0.000671	0.000826	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—NMNAT3—polycystic ovary syndrome	0.000667	0.000821	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000652	0.000803	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000641	0.000789	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	0.000636	0.000783	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000635	0.000782	CbGpPWpGaD
Ximelagatran—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000633	0.000779	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000626	0.000771	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	0.000622	0.000766	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—LPCAT2—polycystic ovary syndrome	0.00061	0.000751	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—SUOX—polycystic ovary syndrome	0.00061	0.000751	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	0.000602	0.000742	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000593	0.000731	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000585	0.00072	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—POMC—polycystic ovary syndrome	0.000577	0.000711	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—INS—polycystic ovary syndrome	0.000574	0.000707	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—ISYNA1—polycystic ovary syndrome	0.000567	0.000698	CbGpPWpGaD
Ximelagatran—CYP2C9—Biological oxidations—POMC—polycystic ovary syndrome	0.000565	0.000696	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—INSR—polycystic ovary syndrome	0.000559	0.000689	CbGpPWpGaD
Ximelagatran—F2—Metabolism of proteins—IGF1—polycystic ovary syndrome	0.000555	0.000684	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	0.000554	0.000682	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000532	0.000655	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000523	0.000644	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PGR—polycystic ovary syndrome	0.000518	0.000638	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	0.000517	0.000637	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	0.000491	0.000605	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	0.000482	0.000594	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	0.000482	0.000594	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000482	0.000593	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000482	0.000593	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000464	0.000571	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	0.000464	0.000571	CbGpPWpGaD
Ximelagatran—F2—Hemostasis—VEGFA—polycystic ovary syndrome	0.000461	0.000568	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000459	0.000566	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	0.000456	0.000562	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000448	0.000552	CbGpPWpGaD
Ximelagatran—F2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000446	0.000549	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000424	0.000522	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000421	0.000519	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—PRL—polycystic ovary syndrome	0.00042	0.000517	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000405	0.000499	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	0.000404	0.000498	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000399	0.000491	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	0.000383	0.000472	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—GNAS—polycystic ovary syndrome	0.00037	0.000455	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	0.000365	0.00045	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	0.000361	0.000445	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000352	0.000434	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000346	0.000426	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	0.000326	0.000401	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	0.000311	0.000383	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	0.000307	0.000378	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000296	0.000365	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	0.000291	0.000358	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—LEP—polycystic ovary syndrome	0.00029	0.000357	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	0.000283	0.000349	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	0.000277	0.000341	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	0.000268	0.00033	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000258	0.000318	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—POMC—polycystic ovary syndrome	0.000249	0.000306	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—INS—polycystic ovary syndrome	0.000247	0.000305	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	0.000247	0.000304	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000239	0.000295	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000239	0.000295	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	0.000239	0.000294	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	0.00023	0.000284	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000227	0.00028	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	0.000221	0.000273	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	0.00022	0.000271	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	0.000219	0.000269	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	0.000217	0.000267	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	0.000206	0.000254	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	0.000203	0.00025	CbGpPWpGaD
Ximelagatran—F2—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000183	0.000225	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—TH—polycystic ovary syndrome	0.000176	0.000217	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	0.000171	0.000211	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	0.000161	0.000198	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000156	0.000193	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	0.000144	0.000177	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	0.000137	0.000168	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	0.00013	0.00016	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	0.000121	0.000149	CbGpPWpGaD
Ximelagatran—F2—Signaling Pathways—IL6—polycystic ovary syndrome	0.000108	0.000133	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	9.8e-05	0.000121	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	9.67e-05	0.000119	CbGpPWpGaD
Ximelagatran—CYP2C9—Metabolism—INS—polycystic ovary syndrome	9.61e-05	0.000118	CbGpPWpGaD
